Cardioprotective effects of angiotensin receptor-neprilysin inhibitors in the real world
Not Applicable
Recruiting
- Conditions
- Heart failure
- Registration Number
- JPRN-UMIN000043197
- Lead Sponsor
- Department of Cardiology, Fukuoka University Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 360
Inclusion Criteria
Not provided
Exclusion Criteria
Patients already receiving ARNI Patients who do not change as a result of consideration Patients with severe liver dysfunction (Child-Pugh classification C)
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular pathways mediate ARNI cardioprotective effects in heart failure patients?
How do ARNIs compare to beta-blockers in reducing heart failure hospitalizations in real-world settings?
Which biomarkers predict response to neprilysin inhibition in heart failure with preserved ejection fraction (HFpEF)?
What adverse events are associated with ARNI use in the JPRN-UMIN000043197 observational study?
What combination therapies enhance ARNI efficacy in managing heart failure symptoms and mortality?